AADvac 1

Drug Profile

AADvac 1

Alternative Names: AADvac-1; Alzheimer's disease vaccine - Axon Neuroscience; Axon peptide 108 conjugated to KLH; Axon peptide 108 coupled to KLH

Latest Information Update: 18 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Axon Neuroscience
  • Class Alzheimer vaccines
  • Mechanism of Action Immunostimulants; Tau protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Alzheimer's disease

Most Recent Events

  • 17 Jul 2017 Axon Neuroscience completes enrolment in the phase II ADAMANT trial for Alzheimer's Disease in Austria, Czech Republic, Slovakia, Slovenia, Sweden, Poland, Romania and Germany (NCT02579252)
  • 03 Apr 2017 AXON Neuroscience and German FTLD Consortium plan a pilot phase I trial for Aphasia (non-fluent variant of Primary Progressive Aphasia (nfvPPA)) in Germany (NCT03174886)
  • 01 Dec 2016 Axon Neuroscience completes the phase I follow-up trial (FUNDAMANT) for Alzheimer's disease in Austria (NCT02031198)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top